3 ms·
In addition (adding on to my comment below), companies don't want the FDA to try to use the outcomes of patients taking the drug for compassionate use as a metr
by Thriptic 11y ago
In addition (adding on to my comment below), companies don't want the FDA to try to use the outcomes of patients taking the drug for compassionate use as a metric of efficacy before a proper phase 2 or 3 clinical trial has been run, for the exact same reasons.